계명대학교 의학도서관 Repository

Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinoma

Metadata Downloads
Author(s)
Min Hee HongSeong Gu HeoYun‐Gyoo LeeHyo Song KimKeon Uk ParkHoon‐Gu KimYoon Ho KoIk‐Joo ChungYoung Joo MinMin Kyoung KimKyu Ryung KimJinseon YooTae‐Min KimHye Ryun KimByoung Chul Cho
Keimyung Author(s)
Park, Keon Uk
Department
Dept. of Internal Medicine (내과학)
Journal Title
Cancer
Issued Date
2020
Volume
126
Issue
20
Keyword
afatinibepidermal growth factor receptor (EGFR) mutationesophageal squamous cell carcinoma (ESCC)predictive biomarkerTP53 mutation
Abstract
Background:
The objective of the current study was to investigate the clinical activity of, safety of, and predictive biomarkers for afatinib, an irreversible pan‐ErbB kinase inhibitor, in patients with recurrent and/or metastatic esophageal squamous cell carcinoma (R/M‐ESCC).

Methods:
Patients with R/M‐ESCC that was refractory to platinum‐based chemotherapy were enrolled in the current multicenter, single‐arm, phase 2 study and received afatinib at a dose of 40 mg/day. The primary endpoint was the objective response rate. Secondary endpoints included progression‐free survival, overall survival, the disease control rate, and the safety profile. To identify predictive biomarkers, single‐nucleotide variations, short insertions/deletions, and somatic copy number alterations were assessed using whole‐exome sequencing and their associations with clinical outcomes were analyzed.

Results:
Among 49 enrolled patients, the objective response rate and disease control rate were 14.3% and 73.3%, respectively. With a median follow‐up of 6.6 months, the median progression‐free survival and overall survival were 3.4 months and 6.3 months, respectively. Treatment‐related adverse events were noted to have occurred in 33 patients (67.3%), with the majority being of grade 1 to 2 (adverse events were graded and recorded based on the National Cancer Institute Common Terminology Criteria for Adverse Events [version 4.03]). Whole‐exome sequencing demonstrated that the ESCC genomes of patients who demonstrated a response to afatinib were enriched with genomic alterations of TP53 and epidermal growth factor receptor (EGFR). As a predictive marker, a score derived from TP53 disruptive mutations and EGFR amplifications and/or missense mutations demonstrated a significant association with the response to afatinib. The score based on the mutational status of EGFR and TP53 achieved a performance of an area under the curve of 0.86 in predicting the sensitivity of afatinib.

Conclusions:
The results of the current study demonstrated that afatinib can confer modest clinical benefits with manageable toxicity in patients with platinum‐resistant R/M‐ESCC. Identification of TP53 alterations and EGFR amplifications may serve as predictive markers with which to identify patients with R/M‐ESCC who may benefit from afatinib.
Keimyung Author(s)(Kor)
박건욱
Publisher
School of Medicine (의과대학)
Citation
Min Hee Hong et al. (2020). Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinoma. Cancer, 126(20), 4521–4531. doi: 10.1002/cncr.33123
Type
Article
ISSN
1097-0142
Source
https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.33123
DOI
10.1002/cncr.33123
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/42995
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
  • 엠바고Forever
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.